Stay updated on Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page
- Check2 days agoChange DetectedThe study's Indiana-based affiliation was updated from Indiana University School of Medicine to Indiana University, changing the credited institution in the collaborators/locations section. This reflects a broader institutional naming for the site and may affect how the record is identified in communications and databases.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s revision/build indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check23 days agoChange DetectedFooter revision label updated from Revision: v3.5.0 to Revision: v3.5.2. This indicates a minor site maintenance update with no changes to study content or data visible on the page.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision: v3.5.0 was added. Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision: v3.4.2 has been added, and the previous funding/operating-status notice has been removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.